Peregrine Asset Advisers Inc. Lowers Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Peregrine Asset Advisers Inc. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 712 shares of the company’s stock after selling 74 shares during the period. Peregrine Asset Advisers Inc.’s holdings in IDEXX Laboratories were worth $294,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories in the third quarter worth $37,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $31,000. Finally, Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $38,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock valued at $6,161,276 over the last ninety days. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 0.0 %

Shares of IDEXX Laboratories stock opened at $452.77 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $431.50 and a 200-day simple moving average of $452.42. The stock has a market cap of $37.08 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 3.39 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

Wall Street Analyst Weigh In

Several research firms recently commented on IDXX. Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Finally, StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.